NSE filing, NSE: QLINE. Summary written from the filing by ALFA Finder's alert engine.
Q-Line Biotech Ltd: key numbers
- Share price
- ₹544.45
- Market cap
- ₹1,270 Cr
- Revenue (annual)
- ₹341.7 Cr
- Net profit (annual)
- ₹55.72 Cr
- P/E (TTM)
- 22.8×Sector 52.0×
- Promoter holding
- 67.51%
- FII holding
- 0.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Q-Line Biotech Ltd
All →Q-Line Biotech Annual General Meeting
Q-Line Biotech Limited held its 16th Annual General Meeting on September 30, 2026. The meeting transacted ordinary and special business, including financial statement adoption and director re-appointments.
Q-Line Biotech Annual General Meeting
Q-Line Biotech has sent a letter to shareholders with bounced emails, providing links to the Annual Report and 16th AGM Notice, scheduled for September 30, 2026.
Q-Line Biotech Annual Report
Q-Line Biotech Limited has submitted its Annual Report for the financial year 2025-26. The full document is accessible via the provided company website link.
Q-Line Biotech Board Meeting Outcome
Q-Line Biotech approved the Board's Report, notice for the 16th AGM, and re-appointment of two Whole Time Directors and the Cost Auditor.
Q-Line Biotech Other Announcement
Q-Line Biotech Limited has re-appointed M/s. P S P & Associates as Cost Auditors for a 12-month term.
- Execution
- 12 months
Q-Line Biotech Partnership
Q-Line Biotech amended its license agreement with Boule Medical AB, Sweden. The revision includes a 25% reduction in license/royalty costs effective from July 2026.
- From
- Boule Medical AB
- Execution
- 5 years
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.